Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The company can report record recognised revenues for FY18 Q4 of $874k – a 71% increase over FY18 Q3 and totalling $2.13m for the full FY18, up 24% on FY17. This came off the back of another strong quarter of unaudited invoiced sales of $708k which totalled $3.17m for the full FY18.
